3D Systems Announces Appointment of The Honorable Alex M. Azar II to its Medical Advisory Board
August 08 2022 - 9:00AM
3D Systems (NYSE:DDD) today announced the appointment of Alex M.
Azar II, former United States Secretary of Health and Human
Services, as the third member of the company’s recently established
Medical Advisory Board (MAB). Secretary Azar will join Dr. Stephen
Klasko, former President and CEO of Thomas Jefferson University and
Jefferson Health, and Dr. David Shulkin, former U.S. Secretary of
Veterans Affairs, as members of the MAB, the primary mission of
which is to provide strategic input, guidance, and recommendations
for the company’s expanding efforts in regenerative medicine.
Secretary Azar is a globally recognized leader in healthcare,
having built a distinguished record of success in both the public
and private sectors. His executive leadership roles include serving
as President of the U.S. Division of Eli Lilly and Company, one of
the largest and most successful healthcare companies in the world,
and a recognized leader in the discovery, development, and
commercialization of pharmaceutical products that have improved the
lives of countless people around the globe. In conjunction with his
leadership role at Eli Lilly, Secretary Azar also served on the
Board of Directors of the Biotechnology Innovation Organization
(BIO), the world’s largest advocacy organization representing the
biotechnology industry.
In addition to his leadership in the private sector, Secretary
Azar has also had a long and distinguished record of public
service. He was appointed General Counsel of the U.S. Department of
Health and Human Services (HHS) in 2001, being unanimously
confirmed by the U.S. Senate. After four years of distinguished
service as General Counsel, he was nominated to be the Deputy
Secretary of HHS and again was unanimously confirmed by the Senate.
Based on his exceptional experience and success in these roles,
Secretary Azar was later nominated and confirmed as the 24th United
States Secretary of Health and Human Services. With oversight
responsibility for critical public health organizations such as the
Center for Disease Control and Prevention, the Food and Drug
Administration, and the Centers for Medicare and Medicaid Services,
Secretary Azar was a recognized champion for improving the health
and wellbeing of all Americans, ranging from healthcare
accessibility and safety to the effective use of new medical
technology to improve patient outcomes and reduce the cost of care.
Included among Secretary Azar’s many accomplishments as HHS
Secretary was his role as one of the architects of Operation Warp
Speed, a public-private partnership initiated by the U.S.
Government that greatly accelerated the development and
manufacturing of multiple, highly effective COVID-19 vaccines and
therapeutics that proved critical to the global effort to fight the
COVID-19 pandemic. Commenting on
Secretary Azar’s appointment, Dr. Jeffrey Graves, president and CEO
of 3D Systems stated, “We are honored and delighted to have
Secretary Azar join our Medical Advisory Board. As a recognized
champion for innovation in both pharmaceuticals and medical
devices, he will be a tremendous resource in furthering our efforts
in regenerative medicine. With the rapid progress we are making in
our ability to print vascularized human tissue, we are entering an
exciting phase of demonstrating efficacy in a broad range of human
organ and non-organ applications, and for use in drug discovery
where the objective is to shorten the time to market for new drug
therapies and reduce dependency on animal testing. With his unique
background in each of these key areas, I am certain that Secretary
Azar’s contributions will be highly impactful.”
In commenting on his appointment, Secretary Azar stated,
“Technological innovation has the capability to dramatically
improve healthcare outcomes and 3D Systems’ efforts in regenerative
medicine offer potential for improving lives in ways that were
difficult to imagine just a few years ago. I am honored and excited
to have this opportunity to advise the company as they push the
boundaries of healthcare innovation and build a world-class
regenerative medicine business.”
Forward-Looking StatementsCertain statements
made in this release that are not statements of historical or
current facts are forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the company to be materially
different from historical results or from any future results or
projections expressed or implied by such forward-looking
statements. In many cases, forward-looking statements can be
identified by terms such as "believes," "belief," "expects," "may,"
"will," "estimates," "intends," "anticipates" or "plans" or the
negative of these terms or other comparable terminology.
Forward-looking statements are based upon management’s beliefs,
assumptions, and current expectations and may include comments as
to the company’s beliefs and expectations as to future events and
trends affecting its business and are necessarily subject to
uncertainties, many of which are outside the control of the
company. The factors described under the headings "Forward-Looking
Statements" and "Risk Factors" in the company’s periodic filings
with the Securities and Exchange Commission, as well as other
factors, could cause actual results to differ materially from those
reflected or predicted in forward-looking statements. Although
management believes that the expectations reflected in the
forward-looking statements are reasonable, forward-looking
statements are not, and should not be relied upon as a guarantee of
future performance or results, nor will they necessarily prove to
be accurate indications of the times at which such performance or
results will be achieved. The forward-looking statements included
are made only as of the date of the statement. 3D Systems
undertakes no obligation to update or revise any forward-looking
statements made by management or on its behalf, whether as a result
of future developments, subsequent events or circumstances or
otherwise, except as required by law.
About 3D Systems More than 35 years ago, 3D
Systems brought the innovation of 3D printing to the manufacturing
industry. Today, as the leading additive manufacturing solutions
partner, we bring innovation, performance, and reliability to every
interaction - empowering our customers to create products and
business models never before possible. Thanks to our unique
offering of hardware, software, materials, and services, each
application-specific solution is powered by the expertise of our
application engineers who collaborate with customers to transform
how they deliver their products and services. 3D Systems’ solutions
address a variety of advanced applications in healthcare and
industrial markets such as medical and dental, aerospace &
defense, automotive, and durable goods. More information on the
company is available at www.3dsystems.com.
Investor Contact:Media Contact: |
|
investor.relations@3dsystems.compress@3dsystems.com |
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/8da76fb4-c498-4397-9355-d3c0c893b492
3D Systems (NYSE:DDD)
Historical Stock Chart
From Mar 2024 to Apr 2024
3D Systems (NYSE:DDD)
Historical Stock Chart
From Apr 2023 to Apr 2024